# The Study is to Evaluate the Safety and Tolerability of SPGL008 Alone or in Combination With BCG in the Patients With NMIBC, and to Determine the RP2D of SPGL008 Alone or in Combination With BCG.To Evaluate the Preliminary Efficacy of SPGL008 Alone or in Combination With BCG.

> **NCT07445308** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Shenyang Sunshine Pharmaceutical Co., LTD.** · enrollment: 120 (estimated)

## Conditions studied

- NMIBC

## Interventions

- **BIOLOGICAL:** SPGL008

## Key facts

- **NCT ID:** NCT07445308
- **Lead sponsor:** Shenyang Sunshine Pharmaceutical Co., LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-12
- **Primary completion:** 2028-11-21
- **Final completion:** 2029-12-21
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-03-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07445308

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07445308, "The Study is to Evaluate the Safety and Tolerability of SPGL008 Alone or in Combination With BCG in the Patients With NMIBC, and to Determine the RP2D of SPGL008 Alone or in Combination With BCG.To Evaluate the Preliminary Efficacy of SPGL008 Alone or in Combination With BCG.". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07445308. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*